Condition: Hepatocellular Carcinoma · Sponsor: Shanghai Zhongshan Hospital
Blood samples will be tested to identify circulating tumor DNA and plasma protein levels to potentially improve prediction of long term prognosis and guide treatment options of patients with hepatocellular carcinoma underwent surgical resection.
This description comes directly from the study's public registry record.
Huichuan Sun · +86-21-64041990 · sun.huichuan@zs-hospital.sh.cn
Always discuss trial participation with your own doctor first.
| Zhongshan Hospital Fudan University | Shanghai, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06382103